文献速递主动脉疾病

慢性肾脏病患者腹主动脉瘤腔内治疗中全程无碘对比剂策略:一项先导研究

Total Iodine Contrast-free Strategy for the Endovascular Management of Abdominal Aortic Aneurysms in Chronic Kidney Disease Patients: A Pilot Study.
PubMed 文献 · Ann Vasc Surg · 2023-03-09

该回顾性先导研究评估了慢性肾脏病(CKD)腹主动脉瘤患者全程(诊断、治疗、随访)不使用碘对比剂的腔内治疗可行性。17例患者采用二氧化碳(CO2)作为首选对比剂行EVAR,随访期间无移植物相关并发症,肾功能保持稳定,无动脉瘤或肾脏相关死亡。

要点

  • 17例CKD患者接受全程无碘对比剂EVAR,围术期无 bail-out 手术。
  • 术前与出院时平均GFR分别为28.14与29.33 ml/min/1.73 m2(P=0.210)。
  • 随访平均16.4个月,无移植物血栓、I/III型内漏、破裂或转换。

核心结论

  • 作者初步经验显示,CKD患者腹主动脉瘤全程无碘对比剂腔内治疗可能可行且安全,似乎能在早中期保持残余肾功能而不增加动脉瘤相关并发症风险,复杂腔内手术也可考虑。

研究设计与样本

  • 回顾性分析前瞻性收集的数据,从2019年1月至2022年11月在本学术机构连续接受EVAR的251例腹主动脉或主髂动脉瘤患者中,筛选解剖适合且合并CKD、术前评估仅用双功超声和平扫CT规划的患者。

主要发现

  • 45例CKD患者择期治疗(45/251,17.9%),其中17例采用全程无碘对比剂策略(17/45,37.8%;17/251,6.8%),7例(7/17,41.2%)行附加计划手术,无术中 bail-out 手术。
  • 术前与出院时平均GFR分别为28.14(SD 13.09;中位数28.06,IQR 20.25)ml/min/1.73 m2与29.33(SD 14.61;中位数27.35,IQR 22)ml/min/1.73 m2(P=0.210)。
  • 平均随访16.4个月(SD 11.89;中位数18,IQR 23),随访期间无移植物血栓、I或III型内漏、动脉瘤破裂或转换等移植物相关并发症。
  • 随访平均GFR为30.39 ml/min/1.73 m2(SD 14.45;中位数30.75,IQR 21.93),与术前和术后相比无显著恶化(P=0.327和P=0.856)。
  • 随访期间无动脉瘤相关或肾脏相关死亡。

临床怎么用

  • 作者认为,对CKD腹主动脉瘤患者,全程无碘对比剂腔内管理可能可行且安全,似乎能保持残余肾功能且不增加早中期动脉瘤相关并发症风险,复杂腔内手术也可考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To retrospectively evaluate the feasibility and effectiveness of the endovascular treatment of patients with abdominal aortic aneurysm and chronic kidney disease (CKD) without the need for using iodinated contrast media throughout the diagnostic, therapeutic, and follow-up pathway. METHODS: A retrospective review of prospectively collected data concerning 251 consecutive patients presenting an abdominal aortic or aorto-iliac aneurysm who underwent endovascular aneurysm repair (EVAR) from January 2019 to November 2022 at our academic institution was performed in order to identify patients with feasible anatomy with respect to manufacturer's instructions for use and with CKD. Patients whose preoperative workout included duplex ultrasound and plain computed tomography for preprocedural planning were extracted from a dedicated EVAR database. EVAR was performed with the use of carbon dioxide (CO2) as the contrast media of choice, whereas follow-up examinations consisted of either duplex ultrasound, plain computed tomography, or contrast-enhanced ultrasound. Primary endpoints were technical success, perioperative mortality, and early renal function variations. Secondary endpoints were all-type endoleaks and reinterventions, midterm aneurysm-related and kidney-related mortality. RESULTS: Forty-five patients had CKD and were treated electively (45/251, 17.9%). Of them, 17 patients were managed with a total iodinated contrast media-free strategy and constituted the object of the present study (17/45, 37.8%; 17/251, 6.8%). In 7 cases, an adjunctive planned procedure was performed (7/17, 41.2%). No intraoperative bail-out procedures were needed. This extracted cohort of patients presented similar mean preoperative and postoperative (at discharge) glomerular filtration rate values, 28.14 (SD 13.09; median 28.06, interquartile range (IQR) 20.25) ml/min/1.73 m2 and 29.33 (SD 14.61; median 27.35, IQR 22) ml/min/1.73 m2, respectively (P = 0.210). Mean follow-up was 16.4 months (SD 11.89; median 18, IQR 23). During follow-up, no graft-related complications occurred in terms of either thrombosis, type I or III endoleaks, aneurysm rupture, or conversion. The mean glomerular filtration rate at follow-up was 30.39 ml/min/1.73 m2 (SD 14.45; median 30.75, IQR 21.93), with no significant worsening in comparison with preoperative and postoperative values (P = 0.327 and P = 0.856 respectively). No aneurysm- or kidney-related deaths occurred during follow-up. CONCLUSIONS: Our initial experience shows that total iodine contrast-free abdominal aortic aneurysm endovascular management in patients with CKD may be feasible and safe. Such an approach seems to guarantee the preservation of residual kidney function without increasing the risks of aneurysm-related complications in the early and midterm postoperative periods, and it could be considered even in the case of complex endovascular procedures.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Esposito D, Fargion AT, Dorigo W, et al. Total Iodine Contrast-free Strategy for the Endovascular Management of Abdominal Aortic Aneurysms in Chronic Kidney Disease Patients: A Pilot Study. Ann Vasc Surg. 2023. PMID: 36906130. doi:10.1016/j.avsg.2023.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。